12/23
06:41 am
anab
GSK's combo therapy trial for advanced ovarian cancer meets primary endpoint [Yahoo! Finance]
Medium
Report
GSK's combo therapy trial for advanced ovarian cancer meets primary endpoint [Yahoo! Finance]
12/19
12:17 pm
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at JPMorgan Chase & Co. from $66.00 to $36.00. They now have an "overweight" rating on the stock.
Low
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at JPMorgan Chase & Co. from $66.00 to $36.00. They now have an "overweight" rating on the stock.
12/18
12:21 pm
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at Truist Financial Co. from $30.00 to $20.00. They now have a "hold" rating on the stock.
Medium
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at Truist Financial Co. from $30.00 to $20.00. They now have a "hold" rating on the stock.
12/12
02:39 pm
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at Wells Fargo & Company from $56.00 to $40.00. They now have an "overweight" rating on the stock.
Low
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at Wells Fargo & Company from $56.00 to $40.00. They now have an "overweight" rating on the stock.
12/12
10:49 am
anab
AnaptysBio Stock Down as Eczema Study Fails to Meet Goals [Yahoo! Finance]
Neutral
Report
AnaptysBio Stock Down as Eczema Study Fails to Meet Goals [Yahoo! Finance]
12/12
10:42 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at Guggenheim from $90.00 to $36.00. They now have a "buy" rating on the stock.
Medium
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at Guggenheim from $90.00 to $36.00. They now have a "buy" rating on the stock.
12/11
06:20 pm
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $40.00 price target on the stock, down previously from $42.00.
Medium
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $40.00 price target on the stock, down previously from $42.00.
12/11
02:19 pm
anab
AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data [Yahoo! Finance]
Medium
Report
AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data [Yahoo! Finance]
12/11
12:25 pm
anab
AnaptysBio, Inc. (NASDAQ: ANAB) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating. They now have a $19.00 price target on the stock, down previously from $52.00.
Medium
Report
AnaptysBio, Inc. (NASDAQ: ANAB) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating. They now have a $19.00 price target on the stock, down previously from $52.00.
12/11
08:40 am
anab
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis [Yahoo! Finance]
High
Report
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis [Yahoo! Finance]
12/11
08:30 am
anab
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
High
Report
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
12/2
07:08 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.
Low
Report
AnaptysBio, Inc. (NASDAQ: ANAB) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.
11/25
11:40 am
anab
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? [Yahoo! Finance]
Low
Report
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? [Yahoo! Finance]
11/16
08:48 am
anab
Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher [Yahoo! Finance]
Medium
Report
Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher [Yahoo! Finance]
11/14
06:29 pm
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $42.00 price target on the stock.
Medium
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $42.00 price target on the stock.
11/12
10:45 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at JPMorgan Chase & Co. from $75.00 to $66.00. They now have an "overweight" rating on the stock.
Low
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at JPMorgan Chase & Co. from $75.00 to $66.00. They now have an "overweight" rating on the stock.
11/7
07:10 am
anab
AnaptysBio Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
AnaptysBio Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/6
02:10 pm
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at HC Wainwright from $55.00 to $52.00. They now have a "buy" rating on the stock.
Low
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at HC Wainwright from $55.00 to $52.00. They now have a "buy" rating on the stock.
11/6
10:28 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $42.00 price target on the stock.
Low
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $42.00 price target on the stock.
11/5
04:15 pm
anab
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
11/5
04:15 pm
anab
Anaptys Announces Participation in November and December Investor Conferences
Medium
Report
Anaptys Announces Participation in November and December Investor Conferences
10/31
08:35 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
Medium
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
10/30
10:08 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target raised by analysts at UBS Group AG from $23.00 to $33.00. They now have a "neutral" rating on the stock.
Medium
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target raised by analysts at UBS Group AG from $23.00 to $33.00. They now have a "neutral" rating on the stock.
10/21
02:22 pm
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target raised by analysts at Guggenheim from $75.00 to $90.00. They now have a "buy" rating on the stock.
Low
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target raised by analysts at Guggenheim from $75.00 to $90.00. They now have a "buy" rating on the stock.